Q-omics provides the consensus-scored ZNF791 profile across patient tissues and cancer cell-line models. ZNF791 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF791 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, ZNF791 RNA expression shows 21,739 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, THCA, and ACC as cancer lineages where ZNF791 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF791 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF791 survival associations across molecular data types. ZNF791 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF791 RNA expression–survival associations across cancer types. High ZNF791 expression shows unfavorable associations in ACC and LGG, but favorable associations in HNSC, KIRC, SCLC and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF791 RNA expression.
This table summarizes ZNF791 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF791. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF791 shows lower tumor expression in THCA, LUAD and UCEC and higher tumor expression in LIHC, HNSC and CHOL. The THCA box plot shows higher ZNF791 RNA expression in normal versus tumor tissue (log2 FC = −0.973, t-test p < 0.001).
This table shows molecular features associated with ZNF791 in patient tissues and cancer cell lines. In patient samples, ZNF791 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF791 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and UPPER_AERODIGESTIVE_TRACT.
